crf

CRF(6-33)(human) is a peptide inhibitor of corticotropin-releasing factor binding protein (CRFBP) that displaces CRF from CRFBP, suppresses body weight gain, and increases motor activity in obese rats in vivo.

CRF (6-33) acetate is a corticotropin-releasing factor binding protein (CRFBP) inhibitor peptide; displaces CRF from CRFBP. Suppresses body weight gain and increases motor activity in obese rats in vivo.

NVS-CRF38 is an antagonist of corticotropin-releasing factor receptor 1 (CRF1).

CRF, bovine (TFA) is a potent agonist of CRF receptor, and displaces [125I-Tyr]ovine CRF with a Ki of 3.52 nM.CRF, bovine is a potent agonist of CRF receptor, and displaces [125I-Tyr]ovine CRF with a Ki of 3.52 nM[1]. CRF shows pEC50s of 11.16, 8.53 and 8

CRF, bovine, is a potent agonist of the CRF receptor and displaces [125I-Tyr]ovine CRF with a Ki of 3.52 nM.

Corticotropin-releasing factor receptor antagonist (Ki values are 17, 5 and 0.97 at human CRF1, rat CRF2α and mouse CRF2β receptors respectively).

α-helical CRF 9-41 acetate is a competitive antagonist of CRF2 (KB = 100 nM) and a partial agonist of CRF1 (EC50 = 140 nM).

Urotensin I acetate (83930-33-0 Free base) is a CRF-like neuropeptide (natural product), a CRF receptor agonist (EC50 as low as 3.5 pM for hCRF1, Ki=0.4 nM), with high affinity and receptor subtype selectivity, used for CRF receptor functional research.

Antalarmin hydrochloride is an antagonist of corticotropin-releasing factor 1(CRF1). Antalarmin hydrochloride produces anti-inflammatory effects and suppresses stress-induced gastric ulceration related to irritable bowel syndrome.

CP 376395 (CP-316311) is an effective and specific Corticotropin-releasing factor 1 (CRF1) receptor antagonist.

Verucerfont (NBI77860) is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) .

Phytic acid dipotassium salt is an endogenous metabolite that inhibits β-secretase 1 (BACE1).

Urocortin, human (Human urocortin I) is a 40 amino acid peptide which is closely related to corticotrophin-releasing factor (CRF).

Astressin acetate is an antagonist of corticotropin releasing factor (CRF) with low affinity for the CRF binding protein and high affinity for the cloned pituitary receptor(Ki = 2 nM).

5-Methyltryptamine hydrochloride is a high-affinity 5-HT1C receptor ligand and a partial agonist of 5-HT. 5-Methyltryptamine hydrochloride protects mice subjected to burn, tourniquet and endotoxin shock.

Corticotropin-releasing factor human (Human CRF; Human corticotropin-releasing factor) is an immunomodulatory neuropeptide that releases ACTH from the anterior pituitary, stimulates the sympathetic nervous system and adrenal medulla, reduces hyperpolarizations, and acts as a functional antagonist of inflammatory mediators.

α-Helical CRF(9-41) TFA acts as a competitive antagonist for the CRF2 receptor, with a binding constant (K B) of approximately 100 nM, and serves as a partial agonist for the CRF1 receptor, exhibiting a half-maximal effective concentration (EC 50) of 140 nM [1] [2].

CRF(6-33)(human) TFA is a competitive inhibitor of the Corticotropin-Releasing Factor Binding Protein (CRF-BP), selectively interacting with CRF-BP without affecting post-synaptic Corticotropin-Releasing Factor receptors, and demonstrates an anti-obesity effect [1] [2].

(D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) is a corticotropin-releasing factor (CRF) antagonist that counteracts the inhibitory effects of IL-1a on luteinizing hormone (LH) production [1].

α-Helical CRF (9-41) is a synthetic peptide antagonist that targets corticotropin-releasing factor (CRF), effectively inhibiting CRF-induced adrenocorticotropic hormone (ACTH) release both in vitro, with isolated rat anterior pituitary cells at concentrations of 0.5 to 5 µM, and in vivo, in non-anesthetized, intact rats at doses ranging from 0.02 to 0.6 µmol/kg. Moreover, it prevents stress-induced ACTH release at a dose of 0.6 µmol/kg in rats and demonstrates the ability to enhance social interaction times in a rat model addressing nicotine-induced conditioned anxiety, in addition to decreasing binge-like ethanol consumption in mice.

Biotin-CRF, human, rat is a biotinylated conjugate of CRF (human, rat). CRF (human, rat) functions as a corticotropin-releasing factor and serves as a marker of the paraventricular nucleus of the hypothalamus.

CRF1 Receptor Antagonist-1 (Compound 2), a CRF1 receptor antagonist, is utilized in research pertaining to congenital adrenal hyperplasia (CAH) [1].

NU/ICRF 500 is a novel anthracenyl-amino acid catalytic inhibitor of topoisomerase II.

ICRF-193 is a DNA topoisomerase II inhibitor.